Hansa Biopharma AB (publ) (24H.F)
| Previous Close | 2.5760 |
| Open | 2.4520 |
| Bid | 2.4820 x 0 |
| Ask | 2.6580 x 0 |
| Day's Range | 2.4520 - 2.4800 |
| 52 Week Range | 1.7140 - 4.9740 |
| Volume | |
| Avg. Volume | 75 |
| Market Cap | 155.052M |
| Beta (5Y Monthly) | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3800 |
| Earnings Date | Jul 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireHansa Biopharma: increase in number of shares and votes
Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby the number of votes increased with 10,474,740 and the share capital increased with SEK 10,474,740.
PR NewswireHansa Biopharma interim report January-March 2024
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024.
PR NewswireHansa Biopharma Expects Strong First Quarter 2024 Sales Performance
Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
